Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12415963 | 0.95 | MAPT (0.51) | MAPTLMNARXFP1FGFR4THRB | |
| SCHEMBL12415966 | 0.87 | MAPT (0.43) | MAPTLMNARXFP1FGFR4ALDH1A1 | |
| SCHEMBL12415964 | 0.87 | MAPT (0.48) | MAPTLMNARXFP1FGFR4THRB | |
| SCHEMBL12415962 | 0.84 | MAPT (0.46) | MAPTLMNARXFP1FGFR4THRB | |
| SCHEMBL12415968 | 0.83 | MAPT (0.42) | MAPTLMNARXFP1FGFR4ALDH1A1 | |
| SCHEMBL12415994 | 0.83 | MAPT (0.52) | MAPTLMNARXFP1FGFR4THRB | |
| SCHEMBL12415960 | 0.80 | FAAH (0.47) | MAPTLMNARXFP1FGFR4DGAT1 | |
| SCHEMBL12415812 | 0.79 | FGFR4 (0.51) | MAPTLMNARXFP1FGFR4THRB | |
| SCHEMBL12416358 | 0.79 | MAPT (0.64) | MAPTLMNARXFP1FGFR4THRB | |
| SCHEMBL12415953 | 0.78 | FGFR4 (0.47) | MAPTLMNARXFP1FGFR4THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172217-A1 | RING-FUSED MORPHOLINE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110172217-A1 | RING-FUSED MORPHOLINE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172217-A1 | RING-FUSED MORPHOLINE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY | PIK3R3, AKT3, AKT2 | MAPT 2999/4885LMNA 4160/4885RXFP1 3699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.